BVLASER secures over RMB 100M Series C to accelerate global expansion and tech innovation

Suzhou BVLASER Technology Co., Ltd. ("BVLASER") recently announced the successful completion of a Series C financing round exceeding RMB 100 million. The round was led by TigerYeah Capital, with participation from several institutions including Optics Valley Industrial Investment, Ennovation Ventures, and Suzhou Leader Ventures. Existing shareholders such as Northern Light Venture Capital and Med-Fine Capital also continued their support in this round. Changhai Capital acted as the exclusive financial advisor.

The successful closing of this financing round not only represents the capital market's strong endorsement of BVLASER's technological prowess, product competitiveness, and business model, but will also provide significant momentum for deepening its globalization strategy, enhancing its brand value, and iterating its core technologies. This investment aims to propel Chinese medical aesthetic laser equipment toward achieving greater breakthroughs in the global high-end market.

As a leading enterprise focused on the R&D, production, and sales of high-end medical aesthetic laser devices, BVLASER has consistently prioritized technological innovation as its core driving force since its inception. It has rapidly established a strong technological moat and a diverse product portfolio. The company has deep expertise in core laser technologies including Erbium, Alexandrite, Thulium, and Picosecond lasers. Over ten of its self-developed products feature technical specifications that consistently rank among the leading in China. Thanks to their precise energy control, safe clinical performance, and reliable stability, these products have gained widespread acclaim in the global market.

To date, BVLASER holds over 100 intellectual property rights. Its products are exported to more than 70 countries and regions worldwide, serving diverse application scenarios such as medical aesthetic institutions and dermatology clinics. The company has achieved consecutive year-on-year revenue doubling over the past three years, solidifying its position as a benchmark enterprise in the global expansion of China's medical aesthetic laser equipment industry.

It is reported that the proceeds from this financing round will be strategically focused on three key directions: first, deepening overseas market expansion, which includes advancing international regulatory registrations and compliance certifications, and enhancing the global after-sales service network to make Chinese laser technology accessible to more users worldwide. Second, comprehensively upgrading brand strength to increase brand recognition and influence in the international high-end market. Third, continuing to iterate core products, with increased R&D investment focused on addressing clinical pain points, and driving the precision and intelligent advancement of laser therapy technology to build a more competitive product ecosystem.